ACA
CYTK icon

American Capital Advisory’s Cytokinetics CYTK Stock Holding History

American Capital Advisory’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5
Closed -$201 – 897
2025
Q1 		$201 Buy
+5
New +$230 ﹤0.01% 735

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

American Capital Advisory's CYTK Position: Q2 2025 in Review

American Capital Advisory sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 5 shares — an estimated $201 sold.

American Capital Advisory first reported a position in CYTK in Q1 2025 and held it in 1 quarter. The position peaked at $201 in Q1 2025. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

  • American Capital Advisory reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
  • American Capital Advisory sold 5 Cytokinetics shares in Q2 2025, an estimated $201.
  • American Capital Advisory first reported a position in Cytokinetics in Q1 2025 and held it in 1 quarter.
  • American Capital Advisory's Cytokinetics position peaked at $201 in Q1 2025.
  • 311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on American Capital Advisory's 13F filing for Q2 2025, filed 5 Aug 2025.